Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 8Esophageal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Hematologic Neoplasms 1Glioma 1Endometrial Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Specimen Handling 3Biopsy 3X-Rays 2Magnetic Resonance Spectroscopy 2veliparib 1trastuzumab biosimilar HLX02 1pertuzumab 1irinotecan sucrosofate 1erdafitinib 1copanlisib 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Ferrosoferric Oxide 1CT-P6 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Malignant Solid Neoplasm × trastuzumab biosimilar HLX02 × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡